Pharmacogenetics for Pain Management in Joint Replacement Patients

Using Pharmacogenetics to Structure Individual Pain Management Protocols for Joint Replacement Patients

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03772535

Acronym

PGx

Enrollment

Registered

2018-12-11

Start date

2018-12-03

Completion date

2021-12-31

Last updated

2021-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthroplasty Complications

Brief summary

The purpose of this study is to determine the ability to use pharmacogenetic testing in a joint replacement practice to prescribe the most effective pain medicine for a specific patient.

Interventions

DIAGNOSTIC_TESTPharmacogenomics Testing

The doctor will use genetic test results to prescribe medications that are a most effective for subject.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

SCREENING

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Primary total hip or total knee arthroplasty cases

Exclusion criteria

* History of narcotic dependence

Design outcomes

Primary

Measure	Time frame	Description
Genetic variants	10 days postoperative	Percent of subject with genetic variants affecting pain medication

Secondary

Measure	Time frame	Description
pain levels	10 days postoperatively	0-10 subjective pain scale

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026